The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
24‐hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects
Ramipril is a new , potent nonsulfhydryl inhibitor of angiotensin converting enzyme . The magnitude and duration of its antihypertensive effect were evaluated in a multicenter , placebo‐controlled , r and omized clinical trial conducted in 100 patients with mild to moderate essential hypertension .  Ramipril significantly reduced both supine and st and ing blood pressures measured 24 h after dosing . Automated blood pressure monitoring showed that ramipril significantly reduced systolic and diastolic pressures for 24 h after dosing . The peak effect occurred between 3 and 6 h after dosing , with approximately 50 % of this effect retained after 24 h. Ramipril was well tolerated ; there was no significant difference between active drug and placebo in the overall incidence of side effects . Ramipril is an effective and well‐tolerated antihypertensive agent , which reduces both supine and st and ing blood pressure over the entire 24‐h period after dosing
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .